CN102379839A - Preparation method of salicylic acid ointment - Google Patents
Preparation method of salicylic acid ointment Download PDFInfo
- Publication number
- CN102379839A CN102379839A CN2010102672857A CN201010267285A CN102379839A CN 102379839 A CN102379839 A CN 102379839A CN 2010102672857 A CN2010102672857 A CN 2010102672857A CN 201010267285 A CN201010267285 A CN 201010267285A CN 102379839 A CN102379839 A CN 102379839A
- Authority
- CN
- China
- Prior art keywords
- salicylic acid
- stir
- product
- vaseline
- dimethyl sulfoxide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a preparation method of a salicylic acid ointment, and the product belongs to the field of pharmacy. The product takes salicylic acid crystal, dimethyl sulfoxide, sorbitan fatty acid ester-80 and vaseline as raw materials, and is successfully prepared through a certain technology. The production process of the product is pollution free, the produced salicylic acid ointment particle is fine and smooth, the salicylic acid content in the product is 1.5%-15%, and accordingly, the product can be applicable to the treatment of various skin diseases.
Description
Technical field:
Product of the present invention belongs to pharmaceutical field, it is characterized in that relating to a kind of compound method of unguentum acidi salicylici.
Background technology:
Unguentum acidi salicylici, outward appearance are yellow ointment, and the department of dermatologry medicine for external use is mainly used in dermatosiss such as treatment psoriasis, superficial skin fungus disease, seborrheic dermatitis, acne, clavus, wart.The different pharmacological actions of salicylic concentration are also different in the ointment, and salicylic acid concentration is facilitated effect at the cutin that has of 1%-3%, and can make keratodermatitis recover normal, and itching-relieving action is arranged simultaneously; 5%-10% has the cutin dissolution, reduces between corneocyte adhering to through adhesive between dissolved cell, or cuticular pH value improves hydration and emollescence causes cutin to be loosened and desquamation through reducing.Because of salicylic concentration is different, pharmacological action is also different, thereby can treat different dermatosiss: treatment seborrheic dermatitis and psoriasis, adopt 2%-10% concentration, and be coated with 1-2 time every day outward; The treatment superficial mycosis adopts 3%-6% concentration; Can use 15% concentration to tinea unguium, be coated with 1-2 time every day outward; The treatment wart adopts 5%-15% concentration, with the diseased region cleaning, and is immersed in the hot water 5 minutes before the medication, eliminates thicker angleplied laminate on it with blade after the soft texture, and medicine is applied on the skin lesion; Treatment clavus adopts 10%-15% concentration, with the diseased region cleaning, and is immersed in the hot water 15～30 minutes before the medication, and contiguous normal skin is coated with the vaseline protection, then medicine is coated, and every day 1 time, removes until pathological changes.Unguentum acidi salicylici is one of the most frequently used clinically ointment, during the traditional method preparation is exactly the salicylic acid crystalline solid to be pulverized the back cross 100 mesh sieves, grinds well with vaseline again; Because salicylic acid is acicular crystal, the difficulty of sieving, and dust from flying when carrying out crushing operation; Big to mucous membrane irritation; Be unfavorable for labor protection, and the finished product outward appearance is coarse, granular sensation is arranged when embrocating skin.Though this method technology is simple, has many defectives.
Summary of the invention:
In order to overcome the defective of aforementioned production method; The present invention provides a kind of new method on the basis of test of many times; This method and the problem of dust from flying when having solved salicylic acid and pulverizing; It is coarse to have solved the finished product outward appearance again, and the defective of granular sensation is arranged when embrocating skin, is all good unguentum acidi salicylici of a kind of outward appearance and result of use.Producing the raw material that this unguentum acidi salicylici uses has: salicylic acid crystalline solid 1%-15%, dimethyl sulfoxide 1%-15%, (dimethyl sulfoxide is a kind of organic compounds containing sulfur, and molecular formula be (CH3) 2S0, and room temperature time is the transparency liquid of no color or smell; Have high polarity, high boiling point, toxicity is extremely low; Heat stability is good can be dissolved in ethanol, propanol; Benzene and chloroform etc. are most, the number Organic substance, are described as " alembroth "; Itself has anti-inflammatory analgetic dimethyl sulfoxide, diuresis, and " catholicon " also is described as in effects such as calmness.) sorbitan fatty acid ester-802%, vaseline 68%-96%.
The present invention can realize through following technical scheme:
A kind of method of batch preparation unguentum acidi salicylici is characterized in that being made up of following steps:
1. send into dimethyl sulfoxide the container of belt stirrer, begin to stir, rotating speed is 15 rev/mins, and add the salicylic acid crystalline solid this moment slowly, is stirred to whole dissolvings.
2. continue to stir, add sorbitan fatty acid ester, stir.
3. vaseline is sent into small-sized chemical reaction kettle, be heated between 45 ℃-55 ℃, be as the criterion with vaseline to molten condition; To be dissolved in the salicylic acid of dimethyl sulfoxide and material that sorbitan fatty acid ester obtains adding agitated reactor this moment; Stir, get product after the cooling, packing gets final product.
The beneficial effect of product of the present invention is: production process is pollution-free, and the unguentum acidi salicylici granule of production is fine and smooth, in the product salicylic content between the 1.5%-15%, thereby the sick treatment of applicable various skin.
The specific embodiment:
Embodiment 1:
Send into the container of belt stirrer to the dimethyl sulfoxide that accounts for total amount 1%, begin to stir, rotating speed is 15 rev/mins, and add the salicylic acid crystalline solid that accounts for total amount 1% this moment slowly, is stirred to whole dissolvings; Continue to stir, adding accounts for total amount 2% sorbitan fatty acid ester, stirs; To account for total amount 96% vaseline and send into small-sized chemical reaction kettle; Be heated between 45 ℃-55 ℃; Be as the criterion with vaseline to molten condition, will be dissolved in the salicylic acid of dimethyl sulfoxide and material that sorbitan fatty acid ester obtains adding agitated reactor this moment, stir; Get product after the cooling, packing gets final product.
Embodiment 2:
Send into the container of belt stirrer to the dimethyl sulfoxide that accounts for total amount 3%, begin to stir, rotating speed is 15 rev/mins, and add the salicylic acid crystalline solid that accounts for total amount 3% this moment slowly, is stirred to whole dissolvings; Continue to stir, adding accounts for total amount 2% sorbitan fatty acid ester, stirs; To account for total amount 92% vaseline and send into small-sized chemical reaction kettle; Be heated between 45 ℃-55 ℃; Be as the criterion with vaseline to molten condition, will be dissolved in the salicylic acid of dimethyl sulfoxide and material that sorbitan fatty acid ester obtains adding agitated reactor this moment, stir; Get product after the cooling, packing gets final product.
Embodiment 3:
Send into the container of belt stirrer to the dimethyl sulfoxide that accounts for total amount 5%, begin to stir, rotating speed is 15 rev/mins, and add the salicylic acid crystalline solid that accounts for total amount 5% this moment slowly, is stirred to whole dissolvings; Continue to stir, adding accounts for total amount 2% sorbitan fatty acid ester, stirs; To account for total amount 88% vaseline and send into small-sized chemical reaction kettle; Be heated between 45 ℃-55 ℃; Be as the criterion with vaseline to molten condition, will be dissolved in the salicylic acid of dimethyl sulfoxide and material that sorbitan fatty acid ester obtains adding agitated reactor this moment, stir; Get product after the cooling, packing gets final product.
Embodiment 4:
Send into the container of belt stirrer to the dimethyl sulfoxide that accounts for total amount 7%, begin to stir, rotating speed is 15 rev/mins, and add the salicylic acid crystalline solid that accounts for total amount 7% this moment slowly, is stirred to whole dissolvings; Continue to stir, adding accounts for total amount 2% sorbitan fatty acid ester, stirs; To account for total amount 84% vaseline and send into small-sized chemical reaction kettle; Be heated between 45 ℃-55 ℃; Be as the criterion with vaseline to molten condition, will be dissolved in the salicylic acid of dimethyl sulfoxide and material that sorbitan fatty acid ester obtains adding agitated reactor this moment, stir; Get product after the cooling, packing gets final product.
Embodiment 5:
Send into the container of belt stirrer to the dimethyl sulfoxide that accounts for total amount 9%, begin to stir, rotating speed is 15 rev/mins, and add the salicylic acid crystalline solid that accounts for total amount 9% this moment slowly, is stirred to whole dissolvings; Continue to stir, adding accounts for total amount 2% sorbitan fatty acid ester, stirs; To account for total amount 80% vaseline and send into small-sized chemical reaction kettle; Be heated between 45 ℃-55 ℃; Be as the criterion with vaseline to molten condition, will be dissolved in the salicylic acid of dimethyl sulfoxide and material that sorbitan fatty acid ester obtains adding agitated reactor this moment, stir; Get product after the cooling, packing gets final product.
Embodiment 6:
Send into the container of belt stirrer to the dimethyl sulfoxide that accounts for total amount 11%, begin to stir, rotating speed is 15 rev/mins, and add the salicylic acid crystalline solid that accounts for total amount 11% this moment slowly, is stirred to whole dissolvings; Continue to stir, adding accounts for total amount 2% sorbitan fatty acid ester, stirs; To account for total amount 76% vaseline and send into small-sized chemical reaction kettle; Be heated between 45 ℃-55 ℃; Be as the criterion with vaseline to molten condition, will be dissolved in the salicylic acid of dimethyl sulfoxide and material that sorbitan fatty acid ester obtains adding agitated reactor this moment, stir; Get product after the cooling, packing gets final product.
Embodiment 7:
Send into the container of belt stirrer to the dimethyl sulfoxide that accounts for total amount 13%, begin to stir, rotating speed is 15 rev/mins, and add the salicylic acid crystalline solid that accounts for total amount 13% this moment slowly, is stirred to whole dissolvings; Continue to stir, adding accounts for total amount 2% sorbitan fatty acid ester, stirs; To account for total amount 72% vaseline and send into small-sized chemical reaction kettle; Be heated between 45 ℃-55 ℃; Be as the criterion with vaseline to molten condition, will be dissolved in the salicylic acid of dimethyl sulfoxide and material that sorbitan fatty acid ester obtains adding agitated reactor this moment, stir; Get product after the cooling, packing gets final product.
Embodiment 8:
Send into the container of belt stirrer to the dimethyl sulfoxide that accounts for total amount 15%, begin to stir, rotating speed is 15 rev/mins, and add the salicylic acid crystalline solid that accounts for total amount 15% this moment slowly, is stirred to whole dissolvings; Continue to stir, adding accounts for total amount 2% sorbitan fatty acid ester, stirs; To account for total amount 68% vaseline and send into small-sized chemical reaction kettle; Be heated between 45 ℃-55 ℃; Be as the criterion with vaseline to molten condition, will be dissolved in the salicylic acid of dimethyl sulfoxide and material that sorbitan fatty acid ester obtains adding agitated reactor this moment, stir; Get product after the cooling, packing gets final product.
Claims (4)
1. the compound method of a unguentum acidi salicylici, it is characterized in that: with salicylic acid crystalline solid 1%-15%, dimethyl sulfoxide 1%-15%, sorbitan fatty acid ester-802%, vaseline 68%-96% is raw material, obtains finished product through following steps.
2. the compound method of a kind of unguentum acidi salicylici according to claim 1; The characteristic of its first step is: send into the container of belt stirrer to dimethyl sulfoxide, begin to stir, rotating speed is 15 rev/mins; Add the salicylic acid crystalline solid this moment slowly, is stirred to whole dissolvings.
3. the compound method of a kind of unguentum acidi salicylici according to claim 1, the characteristic in its second step is: continue to stir, add sorbitan fatty acid ester, stir.
4. the compound method of a kind of unguentum acidi salicylici according to claim 1; The characteristic in its 3rd step is: vaseline is sent into small-sized chemical reaction kettle, be heated between 45 ℃-55 ℃, be as the criterion with vaseline to molten condition; To be dissolved in the salicylic acid of dimethyl sulfoxide and material that sorbitan fatty acid ester obtains adding agitated reactor this moment; Stir, get product after the cooling, packing gets final product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010102672857A CN102379839A (en) | 2010-08-30 | 2010-08-30 | Preparation method of salicylic acid ointment |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010102672857A CN102379839A (en) | 2010-08-30 | 2010-08-30 | Preparation method of salicylic acid ointment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102379839A true CN102379839A (en) | 2012-03-21 |
Family
ID=45819949
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010102672857A Pending CN102379839A (en) | 2010-08-30 | 2010-08-30 | Preparation method of salicylic acid ointment |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102379839A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104840474A (en) * | 2015-04-23 | 2015-08-19 | 夏岚 | Preparation method of externally applied liquid medicine for treating foot corns, callus and verruca plantaris |
| CN106492203A (en) * | 2016-12-07 | 2017-03-15 | 郑州仁宏医药科技有限公司 | A kind of Western medicine combination paste of thorough radical cure corn and preparation method thereof |
| CN108853122A (en) * | 2017-05-15 | 2018-11-23 | 中微知著药物手性技术（大连）有限公司 | For treating the composition of pathogenic fungi of superficial mycosis |
| RU2815010C2 (en) * | 2017-03-21 | 2024-03-11 | Новалид Фарма Инк. | Therapeutic agent for inhibition of phosphodiesterase and associated pathological disorders |
-
2010
- 2010-08-30 CN CN2010102672857A patent/CN102379839A/en active Pending
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104840474A (en) * | 2015-04-23 | 2015-08-19 | 夏岚 | Preparation method of externally applied liquid medicine for treating foot corns, callus and verruca plantaris |
| CN106492203A (en) * | 2016-12-07 | 2017-03-15 | 郑州仁宏医药科技有限公司 | A kind of Western medicine combination paste of thorough radical cure corn and preparation method thereof |
| RU2815010C2 (en) * | 2017-03-21 | 2024-03-11 | Новалид Фарма Инк. | Therapeutic agent for inhibition of phosphodiesterase and associated pathological disorders |
| CN108853122A (en) * | 2017-05-15 | 2018-11-23 | 中微知著药物手性技术（大连）有限公司 | For treating the composition of pathogenic fungi of superficial mycosis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101434608A (en) | Preparation of high-purity ellagic acid | |
| CN106496074A (en) | A kind of preparation method of carbasalate calcium | |
| CN102379839A (en) | Preparation method of salicylic acid ointment | |
| CN108546237A (en) | A method of extracting levodopa by raw material of cat beans | |
| CN101863784A (en) | Methods for preparing and extracting betaine and betaine hydrochloride | |
| JPH06184003A (en) | Complex containing s(+)-phenyl alkane acid and amino sugars | |
| CN1318442C (en) | Dexamethasone sodium phosphate crystal form and its crystallization preparation method | |
| CN107629055A (en) | A kind of triamterene compound and preparation method thereof | |
| CN103864605A (en) | Preparation method of bismuth citrate | |
| CN105685962A (en) | Preparation method of starch-C18 fatty acid compound | |
| CN101544359A (en) | Novel method for nano-selenium through two-step solid phase synthesis | |
| CN101781215A (en) | Method for preparing propyl gallate bulk drug by chemical semi-synthesis | |
| CN104130110A (en) | Method for extracting resveratrol as well as obtained resveratrol and drug composition | |
| CN103483181B (en) | A kind of Calcium zinc gluconate compound | |
| CN102379880A (en) | Preparation method of compound benzoic acid ointment | |
| CN103087138B (en) | Ginsenoside C-K monohydrate crystal and preparation method thereof | |
| CN112168864A (en) | Cannabidiol and NMN preparation formula and preparation method thereof | |
| CN111700870A (en) | Production method of novel NMN + SFE compound medicament | |
| CN1800137A (en) | Chelate of citric acid and calcium malate, and its preparation method and uses | |
| CN109456291A (en) | A kind of method of low temperature rapid crystallization production griseofulvin | |
| CN114983944B (en) | Preparation method of tiamulin fumarate soluble powder | |
| CN103509072A (en) | Preparation method of micro-powder capecitabine | |
| CN109820833B (en) | Rapidly-dissolved ibuprofen soft capsule and preparation method thereof | |
| CN109535022B (en) | Preparation method for improving fluidity of L-carnitine fumarate | |
| CN101190889A (en) | Method for preparing ibuprofen arginine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20120321 |